TransThera Biosciences
Research and development of innovative drugs in oncology, cardiovascular, and inflammatory diseases.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
| investor investor investor investor investor investor investor | €0.0 Valuation: €0.0 | round | |
* | N/A | HKD161m | IPO |
| Total Funding | 000k | ||
Related Content
A clinical-stage biopharmaceutical company specializing in the development of small-molecule drugs to address unmet medical needs. The company's research and development efforts are concentrated on therapeutics for oncology, cardiovascular, and inflammatory diseases.
TransThera Biosciences operates in the biotechnology sector, focusing on advancing its pipeline of drug candidates through clinical trials. The company has received Investigational New Drug (IND) approval from the FDA for its drug candidate TT-00920, intended for the treatment of chronic heart failure. This milestone allows the company to initiate Phase 1 clinical trials to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug.
The company's business model involves strategic research and development collaborations, such as the one with Teijin Pharma, to advance its therapeutic programs. By focusing on areas with significant unmet medical needs, TransThera Biosciences aims to develop and commercialize novel treatments for a global market.
Keywords: biopharmaceutical, clinical-stage, small-molecule drugs, oncology, cardiovascular diseases, inflammatory diseases, drug development, IND approval, Teijin Pharma, TT-00920